Comments
Venus Remedies has received marketing authorisation for its oncology drugs in Ukraine.
This includes Paclitaxel, 100mg/16.7mL, 260mg/43.3mL, 300mg/50mL and 30mg/5mL, Oxaliplatin in concentrations of 50mg/10mL and 100mg/20mL, and Irinotecan in formulations of 100mg/5mL and 40mg/2mL.
The company had been awarded its first disbursement of ₹7.5 crore under the Government’s Production Linked Incentive (PLl) scheme for the financial year 2022-23.
Shares of Venus Remedies closed at ₹332.65 on Thursday’s trade, higher by 1.54 per cent on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.